Search results for "thrombocytosi"

showing 10 items of 24 documents

Sudden infant death caused by a ruptured coronary aneurysm during acute phase of atypical Kawasaki disease

2001

This article describe's a case of atypical Kawasaki disease (AKD) with lack of typical clinical signs and rapid fatal course in a 2-month-old infant, who 1 week before hospitalization demonstrated rhinitis, coughing without fever, and later conjunctival hyperemia and allergic exanthema on chest and arms. On admittance, labwork highlighted the following: leukocytosis, thrombocytosis, elevated sedimentation rate, and positive C-reactive protein. General conditions remained mediocre for 7 days until sudden death occurred. The autopsy confirmed death caused by cardiac tamponade caused by a ruptured inflammated aneurysm of the left anterior descending coronary artery. We believe that the current…

Malemedicine.medical_specialtyThrombocytosisbusiness.industryVascular diseaseCoronary AneurysmInfantAutopsyMucocutaneous Lymph Node Syndromemedicine.diseaseSudden deathPathology and Forensic MedicineSurgeryFatal OutcomeCardiac tamponadeAcute DiseasemedicineHumansKawasaki diseaseLeukocytosismedicine.symptombusinessComplicationSudden Infant DeathHuman Pathology
researchProduct

Essential thrombocythemia terminating in pure erythroleukemia

2004

Transformation into acute leukemia is a rare event in essential thrombocythemia (ET). The blasts are usually of myeloid, rarely of megakaryoblastic differentiation. We present the case of a patient with pure erythroleukemia after a nearly 10-year course of ET, which was treated with hydroxyurea. The patient, a 58-year-old male, presented with an elevated thrombocyte count (926,000/μL) and normal values of hemoglobin and leukocytes. After 10 years of therapy with hydroxyurea, the patient developed acute leukemia of solely erythroid differentiation. Chemotherapy with cytarabine and daunorubicin resulted in incomplete remission. The patient died 2 months after diagnosis of acute erythroleukemi…

Malemedicine.medical_specialtyTime FactorsMyeloidDaunorubicinmedicine.medical_treatmentFatal OutcomeBone Marrowhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansThrombocytosisChemotherapyAcute leukemiaHematologybusiness.industryEssential thrombocythemiaHematologyMiddle Agedmedicine.diseaseCell Transformation Neoplasticmedicine.anatomical_structureImmunologyCytarabineAcute erythroleukemiaLeukemia Erythroblastic Acutebusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Extreme thrombocytosis as a sign of coeliac disease in the elderly: case report

2002

Increase in the number of blood platelets to over 1 000 000/mm 3 in elderly patients is generally considered secondary to a myeloproliferative or neoplastic disease. To report the case of an elderly woman hospitalized for extreme thrombocytosis associated with severe anaemia, who was found to be suffering from coeliac disease. The patient, aged 83 years, was hospitalized presenting with fatigue. Laboratory tests showed microcytic hypochromic anaemia (haemoglobin 4 g/dl) and extreme thrombocytosis (platelet count 1 400 000/mm 3 ). Physical examination was normal, with the exception of marked thinness. There was no evidence of macroscopic bleeding from the gastrointestinal or genitourinary tr…

Pathologymedicine.medical_specialtySettore MED/09 - Medicina InternaAtrophic gastritisPhysical examinationRisk AssessmentSeverity of Illness IndexCoeliac diseaseDiagnosis DifferentialHumanscoeliac disease thrombocytosis iron-deficiency anaemia elderlyMedicineIntestinal MucosaAgedAged 80 and overThrombocytosisLamina propriaHepatologymedicine.diagnostic_testThrombocytosisPlatelet Countbusiness.industryGastroenterologyPrognosismedicine.diseaseCeliac Diseasemedicine.anatomical_structureIron-deficiency anemiaSerum ironAbdomenFemalebusinessEuropean Journal of Gastroenterology & Hepatology
researchProduct

Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients

2010

Abstract Abstract 4113 Introduction: Most of the data related to RARS-T, a rare disorder, involve small cohorts of patients. We aimed to analyze more patients also considering a variety of myelodysplastic or myeloproliferative disorders. Objective: To compare a large cohort of patients with RARS-T to refractory anemia with ringed sideroblasts (RARS), refractory anemia with ringed sideroblasts and multilineage dysplasia (RARS-MD) or essential thrombocythemia (ET) at the time of diagnosis and during disease evolution, in terms of survival and complications. Materials: Data of a European multi-center study was used including 199 cases of RARS-T 173 cases of RARS, 102 cases of RARS-MD and 431 c…

Pediatricsmedicine.medical_specialtyThrombocytosisbusiness.industryEssential thrombocythemiaorganic chemicalsMyelodysplastic syndromesImmunologyCell BiologyHematologyRefractory anemia with ringed sideroblastsmedicine.diseaseBiochemistryGastroenterologybiological factorsbody regionsLeukemiaMyeloproliferative DisordersDysplasiaInternal medicineembryonic structuresmedicineHemoglobinbusinessneoplasmsBlood
researchProduct

Megakaryocytic features useful for the diagnosis of myeloproliferative disorders can be obtained by a novel unsupervised software analysis

2006

An unsupervised method for megakaryocyte detection and analysis is proposed, in order to validate supplementary tools which can be of help in supporting the pathologist in the classification of Philadelphia negative chronic myeloproliferative disorders with thrombocytosis. The experiment was conducted on high power magnification photomicrographs taken from hematoxylin-and-eosin 3 µm thick sections of formalin fixed, paraffin embedded bone marrow biopsies from patients with reactive thrombocytosis or chronic myeloproliferative disorders. Each megakaryocyte has been isolated in the photos through an image segmentation process, mainly based on mathematical morphology and wavelet analysis. A se…

PhotomicrographyThrombocytosisunsupervised software analysisMyeloproliferative DisordersMorphometryMegakaryocyte morphologyMegakaryocyticBone Marrow CellsImage Processing Computer-AssistedHumansMegakaryocytesSoftware61 - MedicinaRetrospective Studies
researchProduct

Thrombocythemic erythromelalgia, primary erythermalgia, and secondary erythermalgia: three distinct clinicopathologic entities.

1994

On the basis of clinical, laboratory, and histopathologic studies, the authors discern three distinct types of red, congested, and burning extremities that need to be distinguished for effective treatment according to their etiology: erythromelalgia in thrombocythemia, primary erythermalgia, and secondary erythermalgia. Each entry is discussed in turn.

ThrombocytosisPathologymedicine.medical_specialtybusiness.industryDiagnostico diferencialPrimary Erythermalgia030204 cardiovascular system & hematologymedicine.diseaseErythromelalgia03 medical and health sciences0302 clinical medicineErythromelalgiaMedicineHumans030212 general & internal medicinebusinessCardiology and Cardiovascular MedicineAngiology
researchProduct

Sepsis in head and neck cancer patients treated with chemotherapy and radiation: literature review and consensus

2015

Abstract: The reporting of infection/sepsis in chemo/radiation-treated head and neck cancer patients is sparse and the problem is underestimated. A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition and management of infections and sepsis. The Delphi appropriateness method was used for this consensus. External expert reviewers then evaluated the conclusions carefully according to their area of expertise. The paper contains seven clusters of statements about the clinical definition and management of infections and sepsis in head and neck cancer patients, which had a consensus. Furthermore, it offers a revie…

cancer patientpathogenesipositron emission tomographyhealthcare associated infectionSettore MED/06 - Oncologia Medicapatient monitoringradiodiagnosimedicine.medical_treatmentChemotherapy; Head and neck cancer; Radiotherapy; SepsisthrombocytopeniaReviewblood cultureorgan injurymedical terminologyMedicineHead and neck cancermetabolic acidosiC reactive proteinHead and Neck Neoplasmmedical specialisttreatment withdrawalconsensus developmentHematologyclinical practicesystemic inflammatory response syndromeItalyOncologyHead and Neck Neoplasmslaboratory testthrombocytosichemically induced/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingchemotherapy; head and neck cancer; radiotherapy; sepsis; oncology; hematology; geriatrics and gerontologyorgan perfusionhospitalizationHumansepsis Head and Neck Neoplasmmedicine.medical_specialtySettore MED/17 - Malattie InfettiveSepsibacterium culturediagnostic approach routefluorodeoxyglucosecancer chemotherapySepsisSDG 3 - Good Health and Well-beingSepsiscancer radiotherapyfollow upChemotherapyHumansinfection riskIntensive care medicineprocalcitonin antimicrobial therapyChemotherapyRadiotherapybusiness.industrydisease predispositionHead and neck cancerlactic acidChemotherapy; Head and neck cancer; Radiotherapy; Sepsis; Humans; Italy; Head and Neck Neoplasms; Sepsis; Hematology; Oncology; Geriatrics and Gerontologymedicine.diseasemortalityDelphi studyRadiation therapyinflammationincidencehyperglycemiaHuman medicineGeriatrics and Gerontologybusiness
researchProduct

Correlation Analysis of Anti-Cardiolipin Antibody/D Dimer/C-Reactive Protein and Coronary Artery Lesions/Multiple-Organ Damage in Children With Kawas…

2021

Aim: Kawasaki disease (KD) is a systemic vasculitis with unknown etiology. In addition to cardiovascular system involvement, it can also have other multiple organs involved. This study is aimed at investigating the correlation between anti-cardiolipin antibody (ACA)/D dimer/C reactive protein (CRP) and coronary artery lesions (CAL)/multiple-organ lesions in children with KD.Methods: Retrospective analysis was performed in 284 KD/IKD patients from May 2015 to April 2016. Among them, 175 were males (61.6%), with average age of 2 years and 5 months old. Patients were divided into ACA+ group and ACA- group, elevated D dimer group (DDE) and normal D dimer group (DDN), and coronary artery injury …

coronary artery lesions (CALs)medicine.medical_specialtyPediatricsGastroenterologyRJ1-570HypoproteinemiachildrenCholestasisInternal medicineD-dimermedicineOriginal ResearchThrombocytosisbiologybusiness.industryC-reactive proteinanticardiolipin antibody (ACA)medicine.diseaseC reactive protein (CRP)stomatognathic diseasesmedicine.anatomical_structureKawasaki disease (KD)Pediatrics Perinatology and Child HealthD dimerbiology.proteinKawasaki diseasebusinessmultiple organ damageSystemic vasculitisArteryFrontiers in Pediatrics
researchProduct

Arterial thrombophilia in primary thrombocythemia. A case report.

1994

One hundred patients with a history of hemorrhoidal disease and suffering from an acute hemorrhoidal attack were randomized into two parallel groups and treated with Daflon 500 mg* (D500) or placebo (PL) under double-blind conditions. Daflon 500 mg was administered at the dosage of three tablets bid the first four days and two tablets bid the following three days. Overall improvement of symptoms was greater in the D500 group than in the PL group, from D2 up to D7. The clinical severity of proctorrhagia, anal discomfort, pain, and anal discharge diminished in both groups but to a greater extent in the D500 group (P < 0.001 for all parameters except protorrhagia, P = 0.006). Inflammation, con…

medicine.medical_specialtyMyocardial InfarctionDaflon 500Placebolaw.inventionHemorrhoidsRandomized controlled triallawEdemaMedicineHumansMyocardial infarctionThrombocytosisbusiness.industryThrombosisMiddle Agedmedicine.diseaseErythromelalgiaSurgeryClinical trialCerebrovascular DisordersAnesthesiaFemalemedicine.symptombusinessComplicationCardiology and Cardiovascular MedicineAngiology
researchProduct

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelof…

2014

Abstract Background: Myelofibrosis (MF) is a clonal neoplastic disease resulting in bone marrow fibrosis, splenomegaly, and debilitating constitutional symptoms. The Janus kinase (JAK) pathway is often dysregulated in MF, and agents targeting this pathway have demonstrated efficacy in this disease. Ruxolitinib (RUX), a potent JAK1/JAK2 inhibitor, demonstrated superiority in spleen volume reduction, symptom improvement, and survival compared with the control arm in the phase III COMFORT-I and COMFORT-II studies. Panobinostat (PAN), a potent pan-deacetylase inhibitor (pan-DACi), inhibits JAK signaling through disruption of the interaction of JAK2 with the protein chaperone heat shock protein …

medicine.medical_specialtyRuxolitinibThrombocytosisCombination therapybusiness.industryAnemiaImmunologyCell BiologyHematologymedicine.diseaseBiochemistryDiscontinuationchemistry.chemical_compoundchemistryInternational Prognostic Scoring SystemInternal medicinePanobinostatImmunologymedicinebusinessMyelofibrosismedicine.drugBlood
researchProduct